{"cluster": 57, "subcluster": 4, "abstract_summ": "CONCLUSION This trial suggests that FBX is as an alternative treatment to HCQ for COVID-19 infection and may be considered in patients with a contraindication or precaution to HCQ.The COVID-19 virus has spread rapidly around the world and there are many patients in multiple countries.Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31) compared with the control group (54.8%, 17 of 31).Patients in HCQ group were given HCQ 400 mg per day for 5 days plus conventional treatments, while those in the control group were given conventional treatment only.This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19.The patients were randomized 1\uff1a1 to HCQ group and the control group.", "title_summ": "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trialEffectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020)ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled StudyHydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].The comparison of the effectiveness of lincocin\u00ae and azitro\u00ae in the treatment of covid-19-associated pneumonia: A prospective study.Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.", "title_abstract_phrases": "CONCLUSION This trial suggests that FBX is as an alternative treatment to HCQ for COVID-19 infection and may be considered in patients with a contraindication or precaution to HCQ.The comparison of the effectiveness of lincocin\u00ae and azitro\u00ae in the treatment of covid-19-associated pneumonia: A prospective study.Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31) compared with the control group (54.8%, 17 of 31).This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19.Exposure: Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization.The patients were randomized 1\uff1a1 to HCQ group and the control group."}